Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Burning Rock Biotech Trading Up 4.8 %
Shares of NASDAQ:BNR traded up $0.16 during trading hours on Friday, reaching $3.51. The stock had a trading volume of 268,112 shares, compared to its average volume of 386,466. The firm has a market cap of $368.94 million, a price-to-earnings ratio of -2.66 and a beta of -0.37. The business's fifty day moving average price is $2.74 and its two-hundred day moving average price is $5.68. Burning Rock Biotech has a 52-week low of $1.74 and a 52-week high of $24.06.
Burning Rock Biotech (NASDAQ:BNR - Get Rating) last announced its quarterly earnings results on Tuesday, May 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.16). The firm had revenue of $21.38 million during the quarter, compared to analysts' expectations of $19.99 million. Burning Rock Biotech had a negative net margin of 165.32% and a negative return on equity of 45.94%. During the same quarter in the previous year, the firm posted ($0.25) EPS. Equities research analysts anticipate that Burning Rock Biotech will post -1.46 earnings per share for the current fiscal year.